:: Altroz - News Magazine HTML Template ::

BioNTech's Q2 Revenue Skyrockets by 102% to €260.8M, Marking a Significant Leap Towards Oncology Innovation

Ryan Peterson 05 Aug, 2025

BioNTech SE reports a 102% surge in Q2 2025 revenue to €260.8M, alongside strategic moves in oncology and mRNA technology, despite a net loss. The company's stock rose 1.09% premar...

Business

Moderna Triumphs Over Biontech and Pfizer in High-Stakes mRNA Patent Battle

Michael Lee 06 Mar, 2025

A Dusseldorf court ruled in favor of Moderna in a patent dispute against Biontech and Pfizer, ordering them to disclose profits and compensate for unauthorized use of patented mRNA...

Business

Moderna Triumphs in Legal Battle: Secures Patent Rights Against Biontech and Pfizer

Olivia Carter 06 Mar, 2025

Moderna secures a significant legal victory in a patent dispute against Biontech and Pfizer, with a Dusseldorf court ruling in its favor. The dispute centers around the unauthorize...